Maximal potential patent foramen diameter does not correlate with the type or frequency of the neurologic event prior to closure

Shelby Kutty, Kimberly Brown, Athar M. Qureshi, Larry A. Latson

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: We analyzed our data on patients undergoing transcatheter patent foramen ovale (PFO) closure to determine if the maximal potential PFO diameter (MPPD) by balloon sizing correlates with important clinical characteristics in this population. Methods: We defined stroke as a focal neurologic deficit lasting >24 h, or focal deficit of shorter duration associated with permanent MRI/CT changes consistent with a focal infarction. Parameters analyzed included age, gender, anticoagulation, hypertension, smoking, MRI/CT findings and MPPD at catheterization. We specifically analyzed the type of neurologic event (stroke/transient ischemic attack, TIA), and number of recorded preceding clinical neurologic events. Results: In 216 consecutive patients, 167 suffered a stroke. MRI/CT changes consistent with one or more embolic events were seen in 156 patients; 49 had a clinical TIA. There was no significant difference in MPPD between stroke (11.0 ± 3.6 mm) and TIA groups (10.9 ± 3.9 mm; 95% confidence interval for difference: -1.33 to 1.00). MPPD did not differ between MRI/CT-positive vs. -negative strokes, and had no correlation with the number of identified pre-closure clinical neurologic events. Conclusions: Continued investigation is needed to determine whether other PFO characteristics, or other anatomic/physiologic parameters, may be useful to identify patients at high risk for cryptogenic stroke/TIA, even before they have their first neurologic event.

Original languageEnglish (US)
Pages (from-to)111-115
Number of pages5
JournalCardiology
Volume113
Issue number2
DOIs
StatePublished - Apr 1 2009

Fingerprint

Nervous System
Stroke
Transient Ischemic Attack
Patent Foramen Ovale
Population Characteristics
Neurologic Manifestations
Catheterization
Infarction
Smoking
Confidence Intervals
Hypertension

Keywords

  • Adult congenital heart disease
  • Patent foramen ovale
  • Pediatric cardiology
  • Stroke

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Cite this

Maximal potential patent foramen diameter does not correlate with the type or frequency of the neurologic event prior to closure. / Kutty, Shelby; Brown, Kimberly; Qureshi, Athar M.; Latson, Larry A.

In: Cardiology, Vol. 113, No. 2, 01.04.2009, p. 111-115.

Research output: Contribution to journalArticle

Kutty, Shelby ; Brown, Kimberly ; Qureshi, Athar M. ; Latson, Larry A. / Maximal potential patent foramen diameter does not correlate with the type or frequency of the neurologic event prior to closure. In: Cardiology. 2009 ; Vol. 113, No. 2. pp. 111-115.
@article{2e65ca70ce78485ba9fd55428d5437b1,
title = "Maximal potential patent foramen diameter does not correlate with the type or frequency of the neurologic event prior to closure",
abstract = "Background: We analyzed our data on patients undergoing transcatheter patent foramen ovale (PFO) closure to determine if the maximal potential PFO diameter (MPPD) by balloon sizing correlates with important clinical characteristics in this population. Methods: We defined stroke as a focal neurologic deficit lasting >24 h, or focal deficit of shorter duration associated with permanent MRI/CT changes consistent with a focal infarction. Parameters analyzed included age, gender, anticoagulation, hypertension, smoking, MRI/CT findings and MPPD at catheterization. We specifically analyzed the type of neurologic event (stroke/transient ischemic attack, TIA), and number of recorded preceding clinical neurologic events. Results: In 216 consecutive patients, 167 suffered a stroke. MRI/CT changes consistent with one or more embolic events were seen in 156 patients; 49 had a clinical TIA. There was no significant difference in MPPD between stroke (11.0 ± 3.6 mm) and TIA groups (10.9 ± 3.9 mm; 95{\%} confidence interval for difference: -1.33 to 1.00). MPPD did not differ between MRI/CT-positive vs. -negative strokes, and had no correlation with the number of identified pre-closure clinical neurologic events. Conclusions: Continued investigation is needed to determine whether other PFO characteristics, or other anatomic/physiologic parameters, may be useful to identify patients at high risk for cryptogenic stroke/TIA, even before they have their first neurologic event.",
keywords = "Adult congenital heart disease, Patent foramen ovale, Pediatric cardiology, Stroke",
author = "Shelby Kutty and Kimberly Brown and Qureshi, {Athar M.} and Latson, {Larry A.}",
year = "2009",
month = "4",
day = "1",
doi = "10.1159/000174290",
language = "English (US)",
volume = "113",
pages = "111--115",
journal = "Cardiology",
issn = "0008-6312",
publisher = "S. Karger AG",
number = "2",

}

TY - JOUR

T1 - Maximal potential patent foramen diameter does not correlate with the type or frequency of the neurologic event prior to closure

AU - Kutty, Shelby

AU - Brown, Kimberly

AU - Qureshi, Athar M.

AU - Latson, Larry A.

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Background: We analyzed our data on patients undergoing transcatheter patent foramen ovale (PFO) closure to determine if the maximal potential PFO diameter (MPPD) by balloon sizing correlates with important clinical characteristics in this population. Methods: We defined stroke as a focal neurologic deficit lasting >24 h, or focal deficit of shorter duration associated with permanent MRI/CT changes consistent with a focal infarction. Parameters analyzed included age, gender, anticoagulation, hypertension, smoking, MRI/CT findings and MPPD at catheterization. We specifically analyzed the type of neurologic event (stroke/transient ischemic attack, TIA), and number of recorded preceding clinical neurologic events. Results: In 216 consecutive patients, 167 suffered a stroke. MRI/CT changes consistent with one or more embolic events were seen in 156 patients; 49 had a clinical TIA. There was no significant difference in MPPD between stroke (11.0 ± 3.6 mm) and TIA groups (10.9 ± 3.9 mm; 95% confidence interval for difference: -1.33 to 1.00). MPPD did not differ between MRI/CT-positive vs. -negative strokes, and had no correlation with the number of identified pre-closure clinical neurologic events. Conclusions: Continued investigation is needed to determine whether other PFO characteristics, or other anatomic/physiologic parameters, may be useful to identify patients at high risk for cryptogenic stroke/TIA, even before they have their first neurologic event.

AB - Background: We analyzed our data on patients undergoing transcatheter patent foramen ovale (PFO) closure to determine if the maximal potential PFO diameter (MPPD) by balloon sizing correlates with important clinical characteristics in this population. Methods: We defined stroke as a focal neurologic deficit lasting >24 h, or focal deficit of shorter duration associated with permanent MRI/CT changes consistent with a focal infarction. Parameters analyzed included age, gender, anticoagulation, hypertension, smoking, MRI/CT findings and MPPD at catheterization. We specifically analyzed the type of neurologic event (stroke/transient ischemic attack, TIA), and number of recorded preceding clinical neurologic events. Results: In 216 consecutive patients, 167 suffered a stroke. MRI/CT changes consistent with one or more embolic events were seen in 156 patients; 49 had a clinical TIA. There was no significant difference in MPPD between stroke (11.0 ± 3.6 mm) and TIA groups (10.9 ± 3.9 mm; 95% confidence interval for difference: -1.33 to 1.00). MPPD did not differ between MRI/CT-positive vs. -negative strokes, and had no correlation with the number of identified pre-closure clinical neurologic events. Conclusions: Continued investigation is needed to determine whether other PFO characteristics, or other anatomic/physiologic parameters, may be useful to identify patients at high risk for cryptogenic stroke/TIA, even before they have their first neurologic event.

KW - Adult congenital heart disease

KW - Patent foramen ovale

KW - Pediatric cardiology

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=56349137323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56349137323&partnerID=8YFLogxK

U2 - 10.1159/000174290

DO - 10.1159/000174290

M3 - Article

C2 - 19023203

AN - SCOPUS:56349137323

VL - 113

SP - 111

EP - 115

JO - Cardiology

JF - Cardiology

SN - 0008-6312

IS - 2

ER -